Lilly gets rare downgrade as analysts question hype over GLP-1 pills and Zepbound’s cash sales


If middle-class Americans lose their jobs to AI, that could mean fewer cash sales of weight-loss drugs like Zepbound.

You May Also Like

The day that stunned Israel: attacks shake faith in intelligence services

It was a day that stunned Israel. Early on Saturday, as much…

Robinhood’s stock climbs as retail trading continues to storm back

Robinhood Markets Inc. saw a big increase in trading volumes during February,…

Biden’s troubled Gaza strategy: ‘the US looks feckless’

When Joe Biden broached the conflict in Gaza at a fundraiser in…

Growth scare sets up markets for fresh bout of volatility

Investors are preparing for renewed volatility when global markets reopen on Monday,…